IVT mRNA Synthesis Considerations Whitepaper

Resources » Learning Center » White Papers » IVT mRNA Synthesis Considerations Whitepaper

Learning Center

Read Our New mRNA Synthesis Whitepaper

Learn the seven most critical considerations when sourcing mRNA for vaccine or therapy development; including plasmid DNA integrity, polyA tail consistency, capping options, uridine modification, LNP packaging, manufacturing workflow, QA/QC, and more.

Cell & Gene Therapy Market Growth Infographic

Download PDF Download PDF

First Name

Please enter a valid first name.

Last Name

Please enter a valid last name.

Email Address

Please enter a valid email address.

Institution

Please enter a valid institution/company.

Country/Region

Please select a valid country.

Postal code

Are you currently working with mRNA?

Are you currently working with mRNA?

Whitepaper Highlights

Effects of plasmid DNA integrity on mRNA quality
Production strategies for improved PolyA tail consistency
mRNA capping options for different cell types
Importance of uridine modification
LNP packaging strategies for improved mRNA delivery
Benefits of integrated manufacturing workflow & customizable QA/QC options

REQUEST A QUOTE

EMAIL

oligo@genscript.com

PHONE

1-877-436-7274

ONLINE FORM

Online Quote Submission

ONLINE FORM

Online Quote Submission